CSIMarket


Acumen Pharmaceuticals Inc   (ABOS)
Other Ticker:  
 


 

Acumen Pharmaceuticals Inc

ABOS's Financial Statements and Analysis



Acumen Pharmaceuticals Inc narrowed first quarter of 2024 net loss per share of $-0.25 compare to net loss per share of $-0.28 recorded in the same quarter a year ago a decrease compare to $-0.23 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.25 $  4 Mill
$+0.03     $+4M    



Acumen Pharmaceuticals Inc 's Revenue rose by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $4 million and declined by -62.89 % sequentially.


Acumen Pharmaceuticals Inc is

More on ABOS's Income Statement



Acumen Pharmaceuticals Inc in the first quarter of 2024 recorded net loss of $-14.873 million, an increase from net loss of $-11.307 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-16.497 million realized in previous quarter.

More on ABOS's Growth

Acumen Pharmaceuticals Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-20 million

More on ABOS's Cash flow Statement


Acumen Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Acumen Pharmaceuticals Inc payed $ -0.85 cash per share, on a free-cash flow basis .

Book value fell by -20.43 % sequentially to $4.38 per share, -112.52% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.38 per share from $ 5.51.

Company issued 11.32 million shares or 23.34 % in Mar 31 2024.


More on ABOS's Dividends

 Market Capitalization (Millions) 215
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) 30
 Revenue (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -56
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Acumen Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Acumen Pharmaceuticals Inc had negative $ -0.85 cash flow per share, on a free-cash flow basis .

Book value fell by -20.43 % sequentially to $4.38 per share, -112.52% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.38 per share from $ 5.51.

Company issued 11.32 million shares or 23.34 % in Mar 31 2024.


More on ABOS's Balance Sheets

 Market Capitalization (Millions) 215
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) 30
 Revenue (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -56
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Acumen Pharmaceuticals Inc Earnings

Acumen Pharmaceuticals Reports $4.005 Million in Revenue for Q1 2024

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focusing on the development of a novel therapeutic for the treatment of Alzheimer's Disease (AD), recently announced its financial results for the first quarter of 2024. The company reported a revenue of $4.005 million during this period. However, Acumen Pharmaceuticals also experienced a net loss of $-14.873 million, which was larger than the previous year's net loss of $-11.307 million.
Despite the financial challenges, Acumen Pharmaceuticals remains dedicated to advancing the fight against AD. In collaboration with Lonza, a renowned partner in pharmaceutical development, the company has signed an agreement to develop a potential ...

Acumen Pharmaceuticals Inc Reports Revenue of $10.791 Million in Q4 2023, Net Loss Increases to $16.497 Million

2. Financial Performance in the Fourth Quarter and Fiscal Year 2023:
In the financial fourth quarter of 2023, Acumen Pharmaceuticals Inc disclosed a revenue of $10.791 million. However, the company also reported a net loss of $16.497 million, which is larger than the loss of $12.866 million incurred during the same period the previous year. For the entire fiscal year 2023, Acumen Pharmaceuticals Inc announced a loss of $52.37 million and revenue of $10.79 million.
It is important to note that the net loss per share has widened to -$1.08 from the previous fiscal year's -$1.06. However, there has been no significant change in the revenue, which remains at $0.00 million compared to the previous year.

Acumen Pharmaceuticals Inc Suffers Operating Deficit in Q3 2023, Seeks Strategies for Recovery



The recent earnings report of Acumen Pharmaceuticals Inc (NASDAQ: ABOS) for the financial period ending September 30, 2023, has sparked concerns within the market. The clinical-stage biopharmaceutical company, focused on developing a therapeutic solution for Alzheimer's disease, revealed an alarming operating deficit of $-16.039 million. This represents a significant deterioration from the previous year's third quarter deficit of $-11.371 million. Coupled with the stock's recent decline and various market indicators, it appears that Acumen Pharmaceuticals Inc is facing significant challenges and market headwinds.
Operating Deficit Growth:
One of the most concerning factors highlighted in Ac...

Acumen Pharmaceuticals Inc, a Rising Player in the Biotech & Pharmaceuticals Industry, Faces Continued Challenges with a Net Loss of $-11.610 Million in Q2 2023

Financial News Report: Overlooked Biotech and Pharmaceuticals Companies and Acumen Pharmaceuticals Inc's Strong Performance
In the world of Biotechnology and Pharmaceuticals, attention is often focused on the large companies dominating the industry. However, a few smaller corporations are emerging with noteworthy earnings and potential for growth. One such company is ABOS, which recently announced an operating loss of $-13.478 million for the second quarter of 2023. This represents a deterioration from the operating loss of $-10.411 million reported in the same quarter of the previous year.
Investors are speculating on whether ABOS will begin to report positive top-line results, which will be a major...

Acumen Pharmaceuticals Inc. Faces Operating Deficit in Q1 2023 Amidst Rapid Growth

Biotechnology and Pharmaceuticals Sector Sees Operating Deficit for Q1 2023
Investors in the biotechnology and pharmaceuticals sector may be interested to learn that researchers are beginning to interpret the first quarter of 2023 results. According to recent reports, the ABOS has announced an operating deficit of $-13.135 million for the January to March 31 2023 reporting season. This is due to the fact that the rising entity has not yet reported any revenue.
However, when compared to the first quarter of 2022, where the ABOS announced an operating deficit of $-9.206 million, this result is not entirely surprising. The organization has also seen a net loss of $-11.307 million, which has expanded fro...


Date modified: 2024-05-15T12:51:43+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com